EPO neem patent revocation revives biopiracy debate

@article{Sheridan2005EPONP,
  title={EPO neem patent revocation revives biopiracy debate},
  author={Cormac Sheridan},
  journal={Nature Biotechnology},
  year={2005},
  volume={23},
  pages={511-512}
}
  • C. Sheridan
  • Published 1 May 2005
  • Engineering
  • Nature Biotechnology
Traditional knowledge exploited by biotech companies warrants some compensation. 

Obligation in a National Legal System:

fairness and for legal requirements and defining “equity” and “justice” as distribution, synallagma and procedure.

Bioprospecting, Access and Benefit Sharing: Revisiting the ‘Grand Bargain’

This chapter sets out the wider international context of bioprospecting, access and benefit sharing, and describes the fraught policy process that has evolved since the adoption of the Convention on

Justice and Benefit Sharing

Benefit sharing as envisaged by the Convention on Biological Diversity (CBD) is a relatively new idea in international law. In the context of non-human biological resources, it aims to guarantee the

Biopiracy after the Nagoya Protocol: Problem Structure, Regime Design and Implementation Challenges

This article assesses the effectiveness of the 2010 Nagoya Protocol to the Convention on Biological Diversity (CBD) for addressing "biopiracy" of genetic resources; that is, their biotechnological

Commutative Justice and Access and Benefit Sharing for Genetic Resources

Abstract The Convention on Biological Diversity (CBD) and its Nagoya Protocol (NP) established an Access and Benefit Sharing (ABS) system between utilizers and providers of genetic resources. ABS is

DISEASE GENE PATENTS, BIOMEDICAL RESEARCH AND PUBLIC HEALTH: A REVIEW ON POLITICAL, LEGAL AND ETHICAL CHALLENGES

Since the first ever patent on a genetically modified organism was granted in 1980 in the US, hundreds of attempts on patenting life forms including human disease genes have been made and many have

Biological Diversity in the Patent System

TLDR
It is concluded that the narrow focus of human innovative activity and ownership of genetic resources is unlikely to be in the long term interest of humanity and a broader spectrum of biodiversity needs to be opened up to research and development based on the principles of equitable benefit-sharing.

Justice and the Convention on Biological Diversity

Justice and the Convention on Biological Diversity Doris Schroeder and Thomas Pogge Benefit sharing as envisaged by the 1992 Convention on Biological Diversity (CBD) is a relatively new idea in

Legal Frameworks for Benefit Sharing: From Biodiversity to Human Genomics

The philosophical principle behind benefit sharing is simple. Those who contribute to scientific research ought to share in its benefits. This is a matter of justice. If benefit sharing does not take

Eric Deibel 3.qxp

This article examines property relations in biotechnology by looking at open source in the sub-disciplines of genomics and bio-informatics within the context established interpretations of common

References

Kenyan dispute illuminates bioprospecting difficulties

Even when going by the book, biotech firms can ruffle feathers in developing countries.